BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34007044)

  • 1. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
    Fan F; Malvestiti S; Vallet S; Lind J; Garcia-Manteiga JM; Morelli E; Jiang Q; Seckinger A; Hose D; Goldschmidt H; Stadlbauer A; Sun C; Mei H; Pecherstorfer M; Bakiri L; Wagner EF; Tonon G; Sattler M; Hu Y; Tassone P; Jaeger D; Podar K
    Leukemia; 2021 Dec; 35(12):3509-3525. PubMed ID: 34007044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
    Fan F; Bashari MH; Morelli E; Tonon G; Malvestiti S; Vallet S; Jarahian M; Seckinger A; Hose D; Bakiri L; Sun C; Hu Y; Ball CR; Glimm H; Sattler M; Goldschmidt H; Wagner EF; Tassone P; Jaeger D; Podar K
    Leukemia; 2017 Jul; 31(7):1570-1581. PubMed ID: 27890927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.
    Mulcrone PL; Edwards SKE; Petrusca DN; Haneline LS; Delgado-Calle J; Roodman GD
    Sci Rep; 2020 Oct; 10(1):17319. PubMed ID: 33057033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
    Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
    Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu.
    Zhang L; Hu Y; Sun CY; Li J; Guo T; Huang J; Chu ZB
    Cancer Sci; 2010 May; 101(5):1117-24. PubMed ID: 20331634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
    Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
    Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in multiple myeloma.
    Vacca A; Ria R; Reale A; Ribatti D
    Chem Immunol Allergy; 2014; 99():180-96. PubMed ID: 24217610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.
    Guo D; Li C; Teng Q; Sun Z; Li Y; Zhang C
    Neoplasma; 2013; 60(1):33-40. PubMed ID: 23067214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.
    Ribatti D; Nico B; Vacca A
    Int Rev Cell Mol Biol; 2015; 314():259-82. PubMed ID: 25619720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
    De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
    Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
    Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
    Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
    Giuliani N; Colla S; Lazzaretti M; Sala R; Roti G; Mancini C; Bonomini S; Lunghi P; Hojden M; Genestreti G; Svaldi M; Coser P; Fattori PP; Sammarelli G; Gazzola GC; Bataille R; Almici C; Caramatti C; Mangoni L; Rizzoli V
    Blood; 2003 Jul; 102(2):638-45. PubMed ID: 12649156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR‑3133 inhibits proliferation and angiogenesis by targeting the JUNB/VEGF pathway in human umbilical vein endothelial cells.
    Xu M; Cao L; Zhang X; Zhuang Y; Zhang Y; Wang Q; Chen Y; Xu L; Sun G
    Oncol Rep; 2020 Oct; 44(4):1699-1708. PubMed ID: 32945523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
    Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
    J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.